EDITOR IN CHIEF: Zhanna D. KOBALAVA, Corresponding Member of the Russian Academy of Sciences, MD, Professor, Head of the Department of Internal Medicine with a course of cardiology and functional diagnostics named after V.S. Moiseev, Medical Institute, RUDN University, Moscow, Russia; ISSN: 2313-0245 (Print) ISSN: 2313-0261 (online) Founded in 1997. Publication frequency: quarterly PUBLISHER: Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University) Open Access: . APC: no article processing charge Peer-Review: double blind. Publication language: Russian, English Indexation: White List, Russian Index of Science Citation, Scopus (Q3 Cite Score), Google Scholar, Ulrich's Periodicals Directory, WorldCat, ResaerchBib, Lens, Research4Life, Dimensions, DOAJ, JournalTOCs, British Library, Bodleian Libraries (University of Oxford), Ghent University Library
Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)
The right of authorship belongs to the authors of articles. The authors transfer the rights to use the article (including the use and distribution of an article in the Open Access) to the publisher of the journal on a non-exclusive license (Publishing Agreement (Public Offer)). At the same time, authors remain full rightsholders. Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'RUDN Journal of Medicine' The Federal State Autonomous Educational Institution of Higher Education "Peoples’ Friendship University of Russia named after Patrice Lumumba” (RUDN University), represented by the Vice-Rector for Scientific Work Andrey Aleksandrovich Kostin, acting under a Power of Attorney No 0044-09/20-198 dated 29.07.2020, hereinafter referred to as the Publisher, on the one hand, hereby offers to the public at large, hereinafter referred to as the Author, on the other hand, hereinafter collectively referred to as the Parties, to enter into this agreement, hereinafter referred to as the Agreement, regarding publication of scholarly materials, hereinafter referred to as the Article, in the Journal named 'RUDN Journal of Medicine', hereinafter referred to as the Journal, under the following terms. 1. General Terms and Conditions 1.1. Pursuant to Clause 2 of the Article 437 of the Russian Federation Civil Code, this Agreement shall be recognized as the public offer, hereinafter referred to as the Offer. Subject to Article 438 of the Russian Federation Civil Code, this Offer shall be deemed to have been completely and irrevocably accepted after the Author had submitted his/her materials by uploading those onto the network electronic system of the article acquisition for review available at the respective section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Information and Communication Network known as the Internet, hereinafter referred to as the Internet. 1.2. Pursuant to the Russian Federation effective law as applicable to compliance with the copyright to electronic information resources, no materials from any site, electronic journal or project may be reproduced, in whole or in part, in any form, either in a hard or soft copy, without a prior consent from the Journal's authors and editorial staff, which may be expressed by posting a respective consent (open license Creative Commons Attribution International 4.0 CC BY-NC) in the relevant section of the Journal's site on the Internet. Whenever any published materials are used within the context of other documents, a reference to the original source needs to be specified. 1.3. The Journal is registered by the Federal Oversight Service for Communications, Information Technologies and Mass Communications (RosKomNadzor). 2. Terms Used in This Agreement The Author is an individual (or individuals) whose creative labor has produced the Article. The Offer Acceptance means a complete and irrevocable acceptance of the Offer under the terms specified in Clause 3 hereof (the Author accepts the Offer by submitting an application to the Publisher, i.e. by uploading the Article along with support materials onto the network electronic system of the article acquisition for review available at the respective section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet). The Journal means an academic periodical named 'BULLETIN of Peoples’ Friendship University of Russia. Series Medicine'. The Application means an electronic request of the Author addressed to the Publisher for publishing the Article in the Journal by uploading the Article and support materials onto the network electronic system of the article acquisition for review available at the relevant section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet). The Publisher is the Federal State Autonomous Educational Institution of Higher Education "Peoples’ Friendship University of Russia named after Patrice Lumumba” (RUDN), being the Journal's founder and publisher. The Article's Metadata means any materials in Russian and English intended to be included into the Science Citation database as per the original version of the Article such as the Article title; authors' details (full last name, first name, patronymic, present employer of each author with indication of the postal code, contact details (e-mail) of each author; abstract; keywords; topical classifications: UDC or any other bibliographic and library classification, and subject indices; bibliography (list of references). The Offer means this document (offer to the Author) to publish an Article by uploading it onto the site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet. The Publication means the act of publishing the Article in the Journal. The Journal's Editorial Staff means a creative team engaged in preparing the Journal for publication. The Editorial Board is an advisory body of the Journal's Editorial Office. The Article means a result of fundamental and applied scholarly efforts in the form of a scholarly material, scientific review material, scientific message, bibliographical review on specific topics of the scholarly study, and background information on Russian and foreign scientists submitted by the Author for publication in the Journal. The Parties mean the Author and the Publisher. The Article Requirements mean requirements to the materials published in the Journal's section named "To Authors" of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/about/submissions#authorGuidelines on the Internet. The Service means publication of the Article in the Journal as per the Author's application. 3. Subject Matter of the Agreement (Offer) 3.1. Subject to this Agreement, the Author shall provide the Publisher at no expense for the copyright duration as stated by the Russian Federation legislation with a non-exclusive license for use of the Author-created Article for the purpose of its publication in the Journal. 3.2. The rights to use this Article as assigned hereunder shall include but not limited to: reproduction of the Article or any part thereof, as well as its metadata in Russian and English in any material form whatsoever, including soft and hard copy forms, as an individual work product in periodicals and/or databases (whether local or web-based) owned by the Publisher and/or any other persons at the discretion of the Publisher; dissemination of the Article or any part thereof, as well as its metadata in Russian and English on any media as part of the Journal and/or databases owned by the Publisher or any other persons, at the discretion of the Publisher, or as an individual work product, worldwide via open access or by subscription without payment of any fee to the Author; making public the Article or any part thereof as well as its metadata in Russian and English so that any person could access the Article from any location and at any time of his/her choice (including via the Internet); issuing permissions to use the Article or any part thereof as well as its metadata in Russian and English to any third parties while notifying the Author by publishing the respective information on the Journal's site without payment of any fee to the Author; processing, including translation of the Article (including translation into foreign languages), and use of the processed (translated) Article in any manner specified above; any other rights, not expressly assigned to the Publisher hereunder, including patent rights to any processes, techniques or methods, and other means, described by the Author in the Article, as well as trademark rights, shall be retained by the Author. 3.3. No territorial restrictions will be applied to the use of rights to the Article. 3.4. This Agreement shall become effective from the time the Article is submitted to the Journal, i.e. uploaded along with support materials onto the network electronic system of the article acquisition for review available at the relevant section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet, hereinafter referred to as the Article Upload. 3.5. The rights shall be assigned by the Author to the Publisher at no expense, and the Article publication in the Journal shall not result in any financial contribution to the Author. 3.6. If the Publisher decides to refuse to publish the Article in the Journal, this Agreement shall cease to be in force. A decision to refuse publication shall be sent to the Author via the e-mail address specified in the Application. 3.7. The Publisher undertakes, throughout the currency of this Agreement, to provide to the Author the services associated with publication of the Article on the Journal's site at URL: http://journals.rudn.ru/index.php/medicine on the Internet. 4. General Terms of the Services Provision 4.1. The Publisher shall provide the services to the Author only if: the Author submits all materials compliant with the Offer requirements by way of the Article Upload; the Author Accepts the Offer. 4.2. The services shall be provided to the Author free of charge. 4.3. If any materials submitted by the Author are found in breach of rules and requirements of this Offer, the Publisher shall have a right to refuse to publish those. 4.4. The Publisher shall not be responsible for any third-party unauthorized use of the data provided by the Author during the currency of this Agreement. 5. Rights and Responsibilities of the Parties 5.1. The Author warrants that: he/she is the valid holder of exclusive rights to the Article; rights granted to the Publisher hereunder were not earlier assigned and will not be assigned to any third parties prior to publication of the Article by the Publisher in the Journal; the Article contains all the references to cited authors and/or sources (materials) that are required by the effective copyright law; the Author has obtained all required licenses to results, facts and other borrowed materials used in the Article where the Author is not a copyright holder; the Article does not contain any materials that may not be published in public sources in accordance with the effective Russian Federation statutory instruments, and the Article publication and dissemination will not involve any disclosure of classified (confidential) information, including state secrets; the Author has familiarized himself with the editorial policy and ethical principles published on the Journal website (http://journals.rudn.ru/medicine/about/editorialPolicies) and the consequences of violating these principles, has advised other Co-authors of the terms of this Agreement and has received consents from all the Co-authors to conclude this Agreement under the terms hereunder. 5.2. The Author undertakes to: submit a manuscript of the Article as per the Requirements to articles; avoid using the soft copy of the Article produced by the Publisher for commercial purposes and in other periodicals; while preparing the Article for publication, the Author undertakes to: make edits specified by readers and approved by the Journal's Editorial Office in the text of the Article and/or revise the Article following the Publisher's request, where necessary; proofread the Article within the timeframes specified in the Journal publication schedule; make only such edits in the proof that are minimally required to correct errors made in the Article original and/or introduce factual and momentary changes. 5.3. The Author is entitled to: pass to any third party a soft copy of the published Article provided by the Publisher pursuant to Clause 5.4 hereof for the Article to be incorporated, in whole or in part, into a scientific information database or repository in order to promote academic or scholarly investigations or for informational and educational purposes subject to the Author, Journal and Publisher being properly referenced. 5.4. The Publisher undertakes to: publish the Author's Article, in soft or hard copy form, in the Journal in accordance with the terms hereof; provide the Author with the proof of the Article and make reasonable edits as requested by the Author, where required, following the Journal's Editorial resolution; provide the Author with the soft copy of the published Article by sending it to the Author's e-mail address within 15 business days of the Journal issue's publication; respect the Author's rights established by the effective law, protect those and use best endeavors to prevent any copyright infringements by third parties. 5.5. The Publisher is entitled to: carry out technical and literary editing of the Article such that its basic content would remain unchanged; review the Article and suggest appropriate changes to the Author, and elect not to publish the Article if the Author fails to introduce such changes; require from the Author and/or other persons that the Journal, Publisher, Author and any other copyright holder, as well as the title of the Article, Journal issue identification and a year of publication as specified in the Journal be properly referenced whenever the Journal and/or the Article, including any individual part or fragment thereof, are used by any of the above-mentioned individuals thereafter; publish preliminary and/or advertising information on the forthcoming publication of the Article in mass media and any other information sources; establish rules (conditions) for acceptance and publication of materials in the Journal. The Journal's Editorial Board, headed by the Editor-in-Chief, shall enjoy an exclusive right to accept and/or reject any materials submitted to the Journal's Editorial Office for publication purposes. No manuscript (tangible medium) submitted by the Author to the Journal's Editorial Office will be subject to return. The Journal's Editorial Staff will not enter into any correspondence regarding the rejection of the Article by the Journal's Editorial Board; suspend provision of services to the Author hereunder temporarily for technical, technological and other reasons preventing the services from being provided for the duration of remedial activities; suspend services hereunder in accordance with civil procedures if: the Article does not correspond to the topics covered by the Journal or by any part thereof, or the submitted material is found insufficient for the individual publication, or the Article design is found at variance with the requirements imposed; the Author is in breach of any other obligations assumed under the Offer arrangement; introduce changes to the Offer as per the procedure established by the Offer. 5.6. Unless otherwise provided or stated herein, the Parties shall refer to the effective legislation of the Russian Federation. 6. Offer Acceptance and Conclusion of the Agreement. The Term of the Agreement 6.1. This Agreement shall become effective when concluded, i.e. when the Author Accepts the Offer by sending an application to the Publisher, that is, by uploading the Article (Article Upload), and remain in effect for five years. 6.2. The Offer Acceptance constitutes an Agreement made in writing (Articles 438 and 1286.1 of the Russian Federation Civil Code) under the Offer terms. 6.3. Unless any of the Parties sends to the other Party a written notification of the Agreement termination no later than two months prior to the end of the specified five-year period, the duration of the Publisher's copyright to the Work shall be automatically extended by the similar period. The number of extensions is not limited. 6.4. The term of the Agreement may not exceed the duration of exclusive rights to the Article pursuant to the Russian Federation legislation. 6.5. Whenever the Author assigns (disposes of) its exclusive rights to the Work to any third party, this Agreement shall remain in effect. 7. Agreement Modification and Termination Procedure 7.1. The Publisher shall have a right to unilaterally modify the terms of this Agreement by giving a prior notice to the Author, at least ten (10) calendar days before such modifications become effective, to the Author's e-mail address specified in the Author's application or via the Journal's site. These modifications shall become effective from the date specified in the respective notice. 7.2. If the Author disagrees with any modification in the terms of this Agreement, the Author shall have a right to submit a written notice of his/her withdrawal from this Agreement by uploading it onto the network electronic system of the article acquisition for review, available at the relevant section of the Journal's site at URL: http://journals.rudn.ru/index.php/medicine/author/submit/1 on the Internet. 7.3. This Agreement may be terminated early: at any time by mutual agreement of the Parties; or otherwise as stipulated herein. 7.4. The Author shall have a right to cancel this Agreement unilaterally by sending the Publisher a respective notice in writing at least sixty (60) calendar days prior to the intended date of the Author's Article publication in the Journal. 7.5. The termination of this Agreement for any reasons shall not release the Parties from responsibility for breach of any Agreement terms during the currency hereof. 8. Liability 8.1. A Party which has failed to perform its obligations under this Agreement, either in full or in part, shall be held liable pursuant to the Russian Federation legislation in force. 8.2. All the data provided by the Author shall be trustworthy. The Author shall be responsible for completeness and reliability of the data provided to the Publisher. The use of untrustworthy information obtained from the Author shall not entail any responsibility upon the Publisher for any adverse effects resulting from its actions based on such untrustworthy information. 8.3. The Author shall take full personal responsibility for compliance with the requirements of the Russian Federation law on advertising, protection of copyright and related rights, protection of trademarks and service marks, and protection of consumer rights. 8.4. The Publisher shall not be held responsible hereunder for: any actions resulting directly or indirectly from the actions of the Author; any loss incurred by the Author whether or not the Publisher was in a position to predict such loss. 8.5. The Publisher shall be relieved from any responsibility for non-compliance with the terms of this Agreement if such non-compliance is a result of a force-majeure event such as an act of state authorities, including adoption of legal instruments, fire, flood, earthquake, other natural calamities, loss of power and/or computer network failure, strikes, civil commotions, riots, and any other similar events. 9. Dispute Resolution Procedure 9.1. Any disputes and disagreements shall be resolved by the Parties by negotiations, and if the Parties fail to reach an agreement, these shall be resolved in accordance with the effective law of the Russian Federation. 9.2. If any disagreements remain unresolved, the Parties shall settle those at the location of the Publisher in accordance with the effective law of the Russian Federation. 10. Miscellaneous 10.1. Any notifications, messages, requests etc., excluding documents which need to be forwarded in original form pursuant to the Russian Federation legislation, shall be deemed to have been received by the Author, if delivered (sent) by the Publisher via the Journal's site, including by publishing those, by fax or e-mail specified in the Application, or using other communication facilities. The Parties acknowledge validity of notifications, messages, requests etc. delivered (sent) using the above-listed methods. 10.2. Where the Publisher becomes subject to any claims related to non-compliance with an exclusive copyright or other intellectual property right of any third party during the writing of the Article or in connection with conclusion of this Agreement by the Author, the Author undertakes to: immediately upon receipt of a Publisher's notification, take measures to settle disputes with such third party, and, where necessary, join the litigation in favor of the Publisher and use its best endeavors to exclude the Publisher from the defendants; reimburse the legal cost, expenses and loss incurred by the Publisher as a result of application of a pre-award relief and measures for execution of a judgment, and damages paid by the Publisher to any third party for the infringement of exclusive copyright and/or other intellectual property rights, as well as other expenditures incurred by the Publisher as a result of infringement by the Author of any warranties provided hereunder. 10.3. Subject to Article 6 of the Federal Law On Personal Data No. 152-FZ dated July 27, 2006, for the period from the conclusion of this Agreement and until the discharge of Parties obligations hereunder, the Author expresses his/her consent to processing of the following personal data by the Publisher: last name, first name, patronymic; taxpayers identification number (TIN); place and date of birth; citizenship details; ID document details; registration and actual location address; e-mail address; mailing address with postal code; contact phone numbers; fax numbers; and details of the employers. 10.4. The Publisher is entitled to process the above personal data for the purpose of this Agreement performance, including for provision of information and reference services to the Author. The processing of personal data shall be understood to mean any handing (operations) with personal data, including collection, systematization, accumulation, storage, refinement (update, alteration), use, distribution (including transfer to third parties), depersonalization, blocking and deletion of personal data in accordance with the effective Russian Federation legislation. 10.5. Where permitted by the Russian Federation legislation, the Author is entitled to withdraw his/her consent to processing of personal data as listed in Clause 10.3 by forwarding a respective notice to the Publisher. Upon receipt of such notice, the Publisher has a right to suspend services. 10.6. The Author will, on a goodwill basis, submit his/her details (and details of each Co-Author subject to their prior consent) to the Journal's Editorial Office consisting of his/her: last name, first name, patronymic, academic rank, academic degree, job title, employer details (name and mailing address), work phone number and e-mail address for the purpose of its general publication in the Journal along with the Article. 11. Registered Address and Particulars of the Publisher Federal State Autonomous Educational Institution of Higher Education "Peoples’ Friendship University of Russia named after Patrice Lumumba” (RUDN University) Address: 6 Mikluho-Maklaya str., Moscow, 117198, Russian Federation TIN 7728073720, CRR 772801001, PSRN 1027739189323. Vice Rector for Scientific Work A.A. Kostin
Meta-analysis of mid-term survival and clinical results of left ventricular surgical reconstruction
Relevance. Post-infarction aneurysm of the left ventricle significantly reduces the length and quality of life of patients. The results of comparisons of different methods for surgical restoration of the left ventricle are ambiguous and often contradictory, complicating the choice of an effective treatment strategy and the ability to objectively assess the survival prospects of such patients. The aim of the meta-analysis is to assess the one-year survival of patients after surgical reconstruction of the left ventricle, to determine the functional class of heart failure, and to study the morphological and functional characteristics of the heart. A comparative analysis of the results of the meta-analytic assessment of patient survival after left ventricle reconstruction using the DOR (SAVER) method will be performed in comparison with other treatment methods. Materials and Methods. As a result of a systematic search in two specialized databases (PubMed, Google Scholar), 1,875 articles were selected. A total of 15 studies were included in the final analysis. The total number of patients in these studies was 1,089. To objectify the assessment of the effectiveness of different surgical approaches, two patient groups were formed. The first group underwent only surgical reconstruction of the left ventricle using the Dor procedure or surgical anterior ventricular endocardial restoration (SAVER); the second group received other methods of surgical ventricular reconstruction, depending on the surgical feasibility. Results. The mean age of the examined patients was 62.1 (95% CI: 60.2-64.1) years. The study included 56% (95% CI: 42-69) men. Anterior aneurysm occurred in 87% (95% CI: 74-99) of patients. The mean EuroSCORE value corresponded to 9.7% (95% CI: 7.3-12.1). Before the operation, the patients had a high functional class of heart failure according to NYHA [3 functional class (95% CI: 2.82-3.1)], low left ventricular ejection fraction [31.3% (95% CI: 29.2-33.3)], dilation of the heart chambers [EDVI - 131.7 mL/m2 (95% CI: 113.1-150.2)]. Meta-analysis of the difference in mean values of ejection fraction in patients before and 1 year after surgery showed an increase of 10.1% (95% CI: 8.01-12.1, p < 0.001). Meta-analysis of the difference in mean values of EDVI and NYHA functional class of heart failure in patients before and 1 year after surgery showed a decrease of 38.8 ml/m2 (95% CI: 28.1-49.6, p < 0.001) and 1.52 (95% CI: 1.3-1.8, p < 0.001), respectively. Conclusion. The meta-analysis showed that one year after surgery, survival rates are 94%, with statistically significant increases in ejection fraction and decreases in functional class of heart failure according to the NYHA scale. The studies did not reveal significant differences in patient survival and clinical outcomes one year after operations performed using different surgical methods. The results indicate the effectiveness of left ventricular surgical reconstruction, providing prolonged improvement in patients’ functional status. However, it should be noted that there was significant heterogeneity among the studies.
Copyright (c) 2026 Mamalyga M.L. https://creativecommons.org/licenses/by-nc/4.0
Surgical strategy for severe trauma and frostbite in polar regions under limited resource conditions
Relevance. Severe trauma remains one of the leading causes of preventable death worldwide. In well-resourced systems, early definitive surgery in a specialized trauma center is the standard of care. In remote Arctic settlements, polar stations and ships, this approach is often unattainable because of limited equipment and personnel, lack of specialists, and prolonged evacuation delays; therefore, a surgeon or general practitioner must make time-critical decisions that directly determine outcomes. Aim: To summarize international experience in surgical care for severe trauma and frostbite in polar regions, analyze the applicability of damage control surgery/damage control resuscitation (DCS/DCR) and prolonged field care (PFC) in resource-limited settings, and outline the role of telemedicine and inter-facility collaboration in supporting surgical decision-making. Materials and methods. A narrative (scoping) review of the literature (1990-2025) was performed using PubMed/MEDLINE, Embase, Scopus, RSCI, and the Cochrane Library, as well as national and institutional guidelines on military, field, and polar medicine. Publications addressing DCS/DCR/PFC, polar surgery, frostbite, evacuation, telemedicine, and organization of medical care in the Arctic and Antarctica were considered. Results and Discussion. Principles of DCS/DCR, originating from military surgery, are adaptable to polar conditions and enable staged management of severe trauma and frostbite when evacuation is delayed and resources are scarce. Key determinants include selecting the location and extent of intervention with respect to logistics, anesthesia and critical care capacity, team composition, and evacuation risk in adverse weather. The concept of a “polar surgical module” is justified as a compact autonomous operating and critical care unit; approaches to triage and surgical tactics for frostbite during prolonged isolation are also discussed. Conclusion. A staged strategy using DCS/DCR/PFC in polar regions aligns operative scope with real resources and evacuation capabilities, reducing the risk of fatal complications. The synthesized experience from military-field and polar surgery can inform protocols for severe trauma care in northern regions and provide a foundation for further research in high-altitude environments and prospective space missions.
Copyright (c) 2026 Skurlatov T.A. https://creativecommons.org/licenses/by-nc/4.0
Employing seamless mesh implants during Lichtenstein hernia repair with the use of insights enabled by artificial intelligence
Relevance. Globally, there are now 32.53 million hernia cases, up from about 23.92 million during the previous 3 decades. Many authors lack statistical knowledge, which could jeopardize healthcare. The aim was to use artificial intelligence as a statistical technique to assess the potential effects of AdhesixTM self-gripping mesh implants, HertraTM mesh implants, and LintexTM glue-fixed mesh implants on the outcomes of inguinal hernia patients who underwent open inguinal hernia repair in Lichtenstein. Materials and Methods. We performed 120 Liechtenstein-compliant inguinal hernia repair procedures on three evenly split patient groups (n = 40) using AdhesixTM, HertraTM, and LintexTM mesh implants. The parameters for comparison were the time-frame of the procedure, hospital-stays, challenges afterwards surgery, and issues that arose during the brief follow-up. Results and Discussion. Patients of the first group were hospitalized for shorter periods of time than those in the second and third groups (group A-4.9 bed /day, group B-4.9.5 bed /day, and group C-4.95 bed /day), with no statistically significant differences. Patients in the first group experience a significantly shorter procedure time, followed by those in the second and third groups (27.8 min, 31.4 min, and 38.9 min respectively). Unlike the third group, which included 3 patients with postoperative discomfort and 1 with postoperative seroma formation, the first and second groups’ postoperative hospitalization stays were free of complications. In contrast to the third group’s 2 patients who experienced mesh migration and hernia recurrence, the first and second groups’ patients experienced no complications during the short-term follow-up. Conclusion. Compared to LintexTM mesh implants, the operative times using AdhesixTM and HertraTM are significantly shorter with no post-operative complications or hernia recurrence.
Copyright (c) 2026 Protasov A.V., Mekhaeel M.S., Salem S.M. https://creativecommons.org/licenses/by-nc/4.0
Auto-graft vs 3D printed implant in reconstruction of frontal bone region
Relevance. Fibrous dysplasia is a pathological condition characterized by the substitution of normal bone with fibrous tissue. The progression of this disorder generally stabilizes with increasing age. Clinically, it may manifest as painless swelling and facial asymmetry. Radiographic examination reveals well-defined margins, intramedullary expansion, maintenance of a smooth cortical contour, and ground-glass appearance. Histologically, the condition is distinguished by the presence of fibrous tissue replacing bone, along with irregularly arranged and randomly oriented bony trabeculae. Current treatment approaches frequently involve surgical intervention utilizing custom-fabricated polyether ether ketone (PEEK) implants or autogenous bone grafts, such as calvarial grafts. Materials and Methods. In the Department of Maxillofacial Surgery of the Russian Children’s Clinical Hospital (RCCH) - a branch of the Federal State Autonomous Educational Institution of Higher Education Russian National Research Medical University named after. N.I. Pirogov of the Ministry of Health of the Russian Federation of Moscow, 65 patients, from 2016 to 2023, were treated for histologically confirmed fibrous dysplasia in the frontal bone. Among them, 2 patients (7 years old girl, and 17 years old boy) were treated with 3D implants made from PEEK, and 2 patients (6 years old boy, and 9 years old girl) were treated with calvarial graft. Results and Discussion. The application of 3D implants has effectively enforce the primary stability of the reconstructed area. The lesion was successfully addressed, achieving an optimal aesthetic outcome characterized by a combination of strength, lightweight properties, and biocompatibility, without any observed complications or failures. Notably, recurrences have been recognized in patients who underwent treatment with calvarial grafts over five years after the operation. Conclusion. PEEK is a thermoplastic polymer characterized by its non-absorbable and nonporous properties, which allows for intraoperative modifications and provides optimal imaging characteristics in the postoperative period. On the other hand, it has been observed that auto-grafts may exhibit a higher risk of failure compared to custom-fabricated implants.
Copyright (c) 2026 Kugushev A.Y., Lopatin A.V., Sadek F., Dagher S. https://creativecommons.org/licenses/by-nc/4.0
Musculoaponeurotic layer structural alterations of the anterior abdominal wall in ventral hernias: insights from CT texture analysis
Relevance. Postoperative ventral hernias (POVH) remain a significant surgical challenge, characterized by remodeling of the musculoaponeurotic layer of the anterior abdominal wall and loss of functional integrity. Computed tomography (CT) texture analysis enables an objective assessment of tissue microarchitecture, facilitates the identification of structural changes, and optimizes preoperative planning and surgical decision-making. Aim. To evaluate structural changes in the musculoaponeurotic layer of the anterior abdominal wall in healthy individuals and patients with W2 and W3 POVH using texture analysis, identify intergroup differences, and determine the topographic-anatomical characteristics of affected tissues. Materials and Methods. This study included 90 patients (30 without hernias, 30 with W2-POVH, 30 with W3-POVH) examined between 2020 and 2024. All patients underwent multislice computed tomography (MSCT), and axial slices were segmented using Roboflow. The resulting masks were analyzed for texture characteristics, including brightness (mean_gray), contrast (contrast), correlation (correlation), kurtosis (kurtosis_gray), skewness (skewness_gray), standard deviation (std_gray), LBP, wavelet analysis, and gabor filtering. Statistical analysis included ANOVA, the Kruskal-Wallis test, and Tukey’s post-hoc analysis. Results and Discussion. Texture analysis revealed significant differences in Wavelet and Gabor response (p < 0.0001). Group 2 exhibited marked structural alterations, while Groups 1 and 3 demonstrated similar tissue characteristics (p > 0.05), suggesting adaptive remodeling in patients with severe hernia defects. Further, Group 2 showed significant changes in contrast (p < 0.0001), correlation (p < 0.0001), and kurtosis (p = 0.001), while brightness (mean_gray) and homogeneity (homogeneity) did not differ significantly (p > 0.05). Conclusion. The most pronounced structural disorganization was observed in W2-POVH patients, indicating morphofunctional instability. In contrast, W3-POVH patients exhibited adaptive changes, suggesting compensatory remodeling. These findings confirm the progressive nature of morphological changes in POVH and highlight the importance of texture analysis for personalized surgical planning.
Copyright (c) 2026 Protasov A.V., Kanakhina L.B., Mazurova O.I. https://creativecommons.org/licenses/by-nc/4.0
Application of monoclonal antibodiesin primary chronic osteomyelitis of the mandible in children
Relevance. Primary chronic osteomyelitis (PCO) is a rare condition that poses diagnostic challenges, primarily affecting children between the ages of 5 and 17. It can occur in various bones, including the mandible in the maxillofacial region. The complexity of distinguishing PCO from infections, tumors, metabolic disorders, and other inflammatory conditions has led to misdiagnoses, resulting in inappropriate treatment strategies and recurrent episodes. Currently, there is no standardized treatment protocol for PCO, with most therapies starting with non-steroidal anti-inflammatory drugs (NSAIDs) to manage symptoms. The purpose of this case report is to find a new treatment approach by using monoclonal antibodies such as Denosumab in the treatment protocol. Monoclonal antibodies like Denosumab have shown promising results by targeting the RANKL-RANK interaction, inhibiting osteoclast activity, and reducing inflammatory bone resorption. Materials and Methods: In the Department of Maxillofacial Surgery of the Russian Children’s Clinical Hospital - a branch of the Federal State Autonomous Educational Institution of Higher Education Russian National Research Medical University named after. N.I. Pirogov of the Ministry of Health of the Russian Federation of Moscow from 2015 to 2023, 45 children underwent inpatient treatment for primary chronic osteomyelitis (PCO). Of these, 17 children received combination therapy, which included decortication with removal of all granulomatous tissue and administration of the drug Denosumab, and that is after receiving negative culture results which conforms the diagnose of PCO. From these 17 patients, a 9-year-old girl with a persistently relapsing course was selected for this article. Results: The treatment methods employed in this clinical case successfully increased the density of the affected area. However, if small cystic components were retained and the sanitation of the granulated tissues was incomplete, a relapse occurred, necessitating repeated surgical treatment. Conclusion: By using this approach, we found that the intervals between collapses have been prolonged; leaving no doubt that the addition of Denosumab to the treatment protocol has played a significant role in achieving this optimal result by maintaining remission stability, even after the symptoms disappeared.
Copyright (c) 2026 Kugushev A.Y., Lopatin A.V., Dagher S. https://creativecommons.org/licenses/by-nc/4.0
Non-invasive diagnostics of monomorphic maculopapular cutaneous mastocytosis
Relevance. Monomorphic maculopapular cutaneous mastocytosis (mMPCM) is a rare and diagnostically challenging form of cutaneous mastocytosis, often mimicking other pigmentary and papular dermatoses. The increasing incidence of mMPCM and the complexity of its differential diagnosis underscore the need for effective, non-invasive diagnostic methods. The aim of the study was to evaluate the dermoscopic features of mMPCM and compare them with findings from optical coherence tomography (OCT) and histopathological criteria, aiming to establish a non-invasive diagnostic algorithm. Materials and Methods. The study included 30 patients aged 14-30 years with mMPCM, observed at the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Russia from 2022 to 2024. All patients underwent clinical examination, dermoscopy, and, in selected cases, OCT imaging. Dermoscopic and OCT findings were systematically compared with histopathological results from skin biopsies. Results and Discussion. Dermoscopic examination of mMPCM lesions revealed increased yellow-brown pigmentation, preservation of skin appendages, unchanged vellus hairs, pigment pseudonetwork, and a weakly expressed asymmetric vascular pattern. Darier’s sign was more frequently detected under dermoscopy than on clinical examination. OCT imaging visualized clusters of mast cells as round or oval low-intensity signal zones, most often located in the reticular dermis, corresponding to histological mast cell infiltrates. The combination of dermoscopy and OCT allowed differentiation of mMPCM from other subtypes of cutaneous mastocytosis based on the depth and distribution of infiltrates. Notably, non-invasive methods provided valuable information for diagnosis and monitoring, reducing the need for routine biopsies. Conclusion. Integrating dermoscopy and OCT into the diagnostic workflow for mMPCM offers informative, non-invasive alternative to traditional histopathology, facilitating early and accurate diagnosis as well as monitoring of disease dynamics and therapeutic efficacy. This study is among the first to systematically compare dermoscopic and OCT findings with histopathological features in mMPCM, highlighting the unique diagnostic potential of these non-invasive techniques for rare forms of cutaneous mastocytosis.
Copyright (c) 2026 Kasikhina E.I., Petrova K.S., Ostretsova M.N., Udzhukhu V.Y., Goeva O.N., Sukhina E.K., Korobova A.A. https://creativecommons.org/licenses/by-nc/4.0
Effect of polydeoxyribonucleotide therapy on the regeneration of long-term non-healing postoperative skin defects
Relevance. Chronic wound healing currently remains a serious problem due to its frequency and associated complications. Polydeoxyribonucleotide therapy, which promotes angiogenesis and tissue regeneration, offers a promising treatment. Aim: to analyze the proliferative and apoptotic activity of regenerative wound surface cells in biopsy samples of long-term non-healing postoperative skin defects at the stages of its healing during polydeoxyribonucleotide therapy. Materials and Methods. We used 24 C57/B1 white mice aged 4-6 months weight 32 ± 0.01g, divided into control (n = 12) and main (n = 12) groups. In the main group 0,38 ml of polydeoxyribonucleotide solution was injected into the bottom and around the surgical ischemic skin defect. On days 4, 7, 10, and 12 after wound modeling, biopsies were embedded in paraffin, stained with hematoxylin and eosin. Biopsy cells in a state of mitotic division, proapoptosis, and with expression of the anti-apoptotic Bcl-2 gene were identified immunohistochemically using primary antibodies Ki-67 (Monoclonal rabbit [SP6] Cell Marque, USA), p53 (Polyclonal rabbit, (GTX50438) GeneTex Inc, USA) and Bcl-2 ([N1N2), (GTX100064) GeneTex Inc, USA), respectively. Secondary antibodies (HiDef Detection™ HRP Polymer system, Cell Marque, USA) conjugated with horseradish peroxidase, were used as secondary antibodies. To adequately represent the structure of the regeneration, the biopsy sections were additionally stained with Mayer’s hematoxylin. The index of antigen-positive cells was determined by counting their number per 100 cells at a microscope magnification ×1350, followed by calculation of the index as a percentage. Statistical analysis included testing for normal distribution using the Shapiro-Wilk test, the Mann-Whitney test for pairwise comparisons, and group data were described using the median, first and third quartiles (interquartile range). Results and Discussion. By day 12 in the main group, the granulation tissue of the biopsy specimens was at the beginning of the third stage of the wound process, while in the control group the second stage of the wound process continued. A stable cell population was formed in the main group 2 days earlier than in the control group. Conclusion. Polydeoxyribonucleotide therapy turned out to be safe and tolerable and accelerated the healing of long-term non-healing postoperative skin defects by 16,67±0,01% by stimulating the proliferative activity of dermal fibroblasts, regulating the expression of the anti-apoptotic gene Bcl-2 and the proapoptotic gene p53 in fibroblast differon cells.
Copyright (c) 2026 Baranovskiy A.G., Shapovalova Y.Y., Baranovskiy Y.G., Kuzminov B.I., Harchenko S.V., Lugin I.A., Kutuzova L.A., Sataieva T.P., Popov S.V., Bakhtiyarov K.R., Yuferov D.Y., Demyashkin G.A. https://creativecommons.org/licenses/by-nc/4.0
Virus-induced changes in peroxisomal markers among HIV-infected patients
Relevance. It is been currently known that viruses rewire the metabolic machinery host’s cell to promote successful viral replication via reprogramming host energy flows, resource, metabolic tools and further, the reorganization of cellular structures. Recent studies indicate that the human immunodeficiency virus significantly reduces the number of peroxisomes in infected cells. However, there is still no clear understanding of the reasons for this apparent HIV intervention. The aim of the study was to confirm the hypothesis about the causes of the decrease in the number of peroxisomes in HIV infection. In this study, changes in several hematological markers of peroxisomal metabolism were assessed in connection with data on the unique role of these organelles in the catabolism of the amino acid L-lysine, the level of which correlates with the level of viral RNA in the blood plasma of HIV-infected individuals. Materials and Methods. A study was conducted on the levels of total cholesterol, catalase, L-lysine, and its derivative L-carnitine among HIV-infected individuals (controllers and patients with rapidly progressive disease) in comparison with similar indicators in cohorts of HIV-infected patients and healthy individuals. Results and Discussion. The study confirms the presence of significant differences in plasma levels of markers associated with peroxisomal metabolism, such as catalase, cholesterol, and the amino acid L-lysine, in the compared groups of HIV controllers and patients with rapidly progressing disease. The most negative changes in peroxisomal markers were detected among patients with accelerated HIV disease progression and, to a lesser extent, in individuals from the overall cohort. Conclusion. The results of this study indicate that HIV interference with host peroxisome biogenesis is accompanied by a concomitant dysregulation of peroxisomal enzyme systems and L-lysine-related substrates. Virus-induced reprogramming of the catabolism of this essential amino acid indirectly confirms the hypothesis of a key role of L-lysine in the HIV life cycle and is a factor in the successful implementation of the reproductive strategy of the human immunodeficiency virus.
Copyright (c) 2026 Butorov E.V. https://creativecommons.org/licenses/by-nc/4.0
Bacteriophages: an alternative to antibiotics in the era of antimicrobial resistance
Relevance. Antibiotic resistance is one of the most urgent global health challenges, caused by the widespread and often inappropriate use of antibiotics and by evolutionarily entrenched bacterial adaptation mechanisms. By 2050, antimicrobial resistance is projected to cause up to 10 million deaths annually, underscoring the urgent need for novel therapeutic strategies. In this context, bacteriophages - viruses that specifically infect bacteria - emerge as a promising alternative to antibiotics. This review analyzes the primary mechanisms by which bacteria develop resistance, including β-lactamase-mediated drug inactivation, efflux pump activity, target modification, and horizontal gene transfer, as well as the clinical significance of the ESKAPE pathogen group. We discuss phage classification into lytic and lysogenic types, their morphological characteristics, and life cycles. Special attention is given to modern methods of phage delivery (oral, topical, parenteral, and inhalational) and to phage-host immune interactions, including antibody production and immunomodulatory effects on macrophages, neutrophils, and lymphocytes. A dedicated section addresses the clinical applications of phage therapy in surgery and chronic wound management. We summarize outcomes from cardiothoracic, abdominal, and orthopedic surgical settings, combined phage-antibiotic regimens, and the implementation of vacuum-assisted wound therapy with phage instillation, all of which demonstrate accelerated healing, reduced microbial burden, and fewer postoperative complications. Conclusion. Phage therapy offers several advantages - high specificity, efficacy against multidrug-resistant strains, compatibility with antibiotics, and minimal side effects. On the other hand, its broad clinical implementation requires addressing challenges such as standardizing phage preparation manufacturing, establishing centralized phage banks, developing algorithms for strain selection in personalized therapy, and addressing regulatory barriers. Further randomized clinical trials and the creation of an appropriate legal and regulatory framework are essential for the full utilization of phages as an effective tool in the fight against antibiotic resistance.
Copyright (c) 2026 Khamidulin G.V., Paskhalova Y.S., Mitish V.A., Ushakov A.A., Orujeva S.A., Magomedova S.D., Boranenkov V.K. https://creativecommons.org/licenses/by-nc/4.0
Antibiotic use density in trauma intensive care unit at a tertiary care hospital in Western Rajasthan
Relevance. The excessive use of antibiotics is a public health issue that has hampered poor and middle-income nations and is linked to rising healthcare expenses and antimicrobial resistance, which is regarded as an important risk to world health. In addition, resistance raises expenses, prolongs hospital stays for patients, and causes mortality. Defined daily dose (DDD) represents the average adult daily maintenance dose of a specific drug applied according to its primary indication. Antibiotic use density is expressed as defined daily doses/ 100 patient-days. Aim. The aim of this study is to evaluate the pattern of usage of antibiotics and to find out antibiotic use density in trauma intensive care unit (ICU). Materials and Methods. In this prospective observational study prescription data of 100 consecutive patients at admission into the trauma ICU was audited. Patients of all age of either gender admitted in the trauma ICU during the study period, which have been prescribed with antibiotics. The study was conducted over a period of eight months from August 2022 March 2023. During this period, all the included patients were followed up for their entire duration of stay in trauma ICU. Results and Discussion. The prescriptions of 100 consecutive patients admitted into the ICU were analyzed. On analyzing comorbidities it was noted that 79% were affected with contusions in brain/ intracerebral hemorrhage/ subdural hematoma followed by 5% with pnumothorax. According to DDD/100 bed days in our study piperacillin+tazobactam (10.64), cefoperazone+sulbactam (5.21), amikacin (7.5), vancomycin (3.2) and linezolid (3.2) were most consumed drugs in trauma ICU patients. Conclusion. Present study results conclude that overuse of antibiotics can cause antibiotic resistance, increased duration of stay in hospitals and reason of mortality.
Copyright (c) 2026 Verma D.K., Gehlot A., Kumari N., Rathore R. https://creativecommons.org/licenses/by-nc/4.0